Clinical Trial Update: Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia [Phase 1]

View source ↗

Summary

A Phase 1 safety and pharmacokinetic study of escalating doses of SP-420, an iron chelator, in patients with beta-thalassemia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Iron Overload

Drugs mentioned

• SP-420

Snippet

Sponsor: Sideris Pharmaceuticals | Conditions: Iron Overload, Beta-Thalassemia | Phase 1 | Status: TERMINATED